Bionano Genomics (BNGO) Q2 2026 Earnings Call Transcript
Bionano Genomics (BNGO) reported Q2 2026 revenue of $8.2 million, up 21% year over year, driven by higher OGM consumables sales. Flow cell sales rose 27% to 9,219 units, though the company said it is backordered due to manufacturing constraints. Installed base was 397 systems. Adjusted gross margin was 53%. Full-year 2026 revenue guidance is $31 million to $33 million.
How this was made
The 30-second read
Why it matters
Management emphasized recurring consumables growth and clinical evidence, while explicitly flagging supply backorders and timing risk for Q3 revenue. The company also reported full retirement of senior secured convertible debt and discussed an Ionic purification expansion to support higher-margin recurring revenue.
Market read
Traders can update expectations for Q3 and FY 2026 based on management’s revenue guidance and the stated plan to relieve flow-cell backorders by late 2026, while weighing timing risk from large near-quarter-end orders.
What to watch
The guidance is tied to large orders near quarter-end and manufacturing capacity; traders should monitor whether the company’s stated backorder resolution by late 2026 actually translates into improved shipment cadence and reduced timing slippage.
Background
Bionano’s Q2 2026 earnings call focuses on consumables adoption (OGM flow cells), installed-base utilization, and ongoing flow-cell manufacturing constraints.
Ticker impact
Bionano reported Q2 2026 revenue of $8.2M, guided FY 2026 revenue to $31M-$33M, and said flow-cell manufacturing backorders should ease by late 2026.
Likely two-sided reaction: upside from strong consumables/flow-cell demand and debt retirement, offset by risk that manufacturing backlogs and large late-Q3 orders delay revenue.
Key new decision inputs are management’s updated revenue guidance, explicit backorder/timing risk, and the stated plan to expand Ionic purification in Q4 2026. These are actionable for positioning around Q3/Q4 expectations, but the excerpt does not include consensus or the stock’s immediate move.
Market effects
Signals that optical genome mapping adoption is translating into consumables growth, but supply-chain capacity remains the binding constraint for the sector’s near-term revenue conversion.
International (Europe) contributed the majority of revenue, reinforcing that adoption momentum is not limited to the US.
Clinical evidence expansion (oncology and reproductive health) supports longer-cycle demand, while manufacturing backlogs can still create quarter-to-quarter volatility.
Counterpoint
Strong flow-cell unit growth may be partially offset by delayed deployments and software timing, so reported demand could be pulling revenue forward from later quarters rather than creating net new growth.
Key entities
- companyBionano Genomics, Inc.
OGM platform provider reporting Q2 2026 results, issuing Q3 and FY 2026 revenue guidance, and addressing flow-cell manufacturing backorders.
- executiveAlbert A. Luderer
Interim CEO who attributed growth to customer adoption and highlighted manufacturing constraints and guidance timing risk.
- executiveMark Adamchak
Accounting officer who participated in the call.
